Medical news and careers, clearly connected
CareZelo
English
Menu

Public health updates

Public healthCanada

Novo Nordisk transitions 3 mg Rybelsus tablets to 1.5 mg formulation

Novo Nordisk Canada reports its Rybelsus (semaglutide) 3 mg tablet is in an actual shortage anticipated from Aug 30, 2026, with no estimated end date. The company says the current 3 mg formulation will transition to the equivalent new optimized formulation of Rybelsus 1.5 mg — a formulation change, not a supply failure.

Semaglutide is widely prescribed for type 2 diabetes — patients on the 3 mg tablet should plan the switch to the 1.5 mg formulation with their prescriber.

Ask about this brief

Answers are written by AI from this brief and can be wrong. Check the original source before you act.

2 free questions a day without an account. Members ask as often as they like, free.

Not medical, legal or immigration advice. Questions are kept anonymously to improve our briefs.

Read the original

Official source: Novo Nordisk transitions 3 mg Rybelsus tablets to 1.5 mg formulation (opens in a new tab) — Health Product Shortages Canada

Report a problem

AlertPublic healthCanada

Cheplapharm reports critical Tier 3 shortage of 50 mg etoposide capsules

Cheplapharm Arzneimittel reports its Vepesid (etoposide) 50 mg oral capsule is in a Tier 3 critical shortage after a disruption in manufacturing. The shortage was anticipated from Sep 4, 2026 and its estimated end date is unknown; the Oct 27 update confirmed the shortage is now actual rather than anticipated.

Etoposide is a chemotherapy drug — a Tier 3 critical shortage means cancer care teams need alternatives or allocation plans now.

Official source: Health Product Shortages Canada (opens in a new tab)

AlertPublic healthCanada

Pfizer reports critical shortage of intravenous dextrose solution until February 15

Pfizer Canada reports its Dextrose Injection USP (dextrose 500 mg solution for intravenous use, 10 x 50 mL Ansyr) is in a Tier 3 critical shortage after a disruption in manufacturing. The actual shortage began Sep 9, 2026 and is estimated to end Feb 15, 2027.

IV dextrose is a hospital staple for fluids and low-blood-sugar care — a Tier 3 shortage affects wards across the system.

Official source: Health Product Shortages Canada (opens in a new tab)

Public healthCanada

Formative Pharma reports upcoming supply shortage for 60 mg cabazitaxel injections

Formative Pharma reports its Cabazitaxel for Injection 60 mg solution for intravenous use faces an anticipated shortage from Apr 30, 2027, citing a Health Canada supplement delay. The company says the product is on 100% allocation at CPDN and no estimated end date is given.

Cabazitaxel is a chemotherapy drug — oncology teams should plan supply well ahead of the April 2027 start.

Official source: Health Product Shortages Canada (opens in a new tab)

Due in 23 daysPublic healthCanada

Formative Pharma reports upcoming supply shortage for 45 mg cabazitaxel injections

Formative Pharma reports its Cabazitaxel for Injection 45 mg solution for intravenous use faces an anticipated shortage from Nov 20, 2026, citing a Health Canada supplement delay. The company says the product is on 100% allocation at CPDN and no estimated end date is given.

Cabazitaxel is a chemotherapy drug — oncology teams should plan supply ahead of the November start.

Official source: Health Product Shortages Canada (opens in a new tab)